ENDPOINTS

Viking Therapeutics taps CordenPharma to manufacture its obesity drugs

Viking Therapeutics has contracted CDMO CordenPharma for a total of $150 million to make billions of clinical and commercial doses of its GLP-1/GIP receptor agonist for weight loss. The Swiss CDMO will manufacture the API ...

Mar 12, 2025 - 14:46
 0
Viking Therapeutics taps CordenPharma to manufacture its obesity drugs
Viking Therapeutics has contracted CDMO CordenPharma for a total of $150 million to make billions of clinical and commercial doses of its GLP-1/GIP receptor agonist for weight loss. The Swiss CDMO will manufacture the API ...
Read More

Tags:

Previous Article

Retrieve Medical Holdings Inc. Announces Letter of Intent to Acquire Cúratus LLC...

Next Article

Insilico nabs $110M Series E for AI drug discovery after stalling Hong Kong IPO ...

Related Posts

Algo’s topical pain treatment fails Phase 2 study with overperforming placebo

Algo’s topical pain treatment fails Phase 2 study with ...

Feb 18, 2025  0

Can amylin drugs take over from GLP-1s in obesity? Partnerless Zealand thinks so

Can amylin drugs take over from GLP-1s in obesity? Part...

Feb 20, 2025  0

Biohaven’s ion channel drug fails pivotal bipolar mania study

Biohaven’s ion channel drug fails pivotal bipolar mania...

Mar 3, 2025  0